Phase III trial of MK-4117 in Japanese subjects with perennial allergic rhinitis

Phase 3, randomised, double-blind trial of desloratadine in perennial rhinitis (3 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in total nasal symptom score at Week 2 (MK-4117 10 mg vs placebo) and Change from baseline in total nasal symptom score at Week 2 (MK-4117 10 mg and 5 mg vs placebo).